Document Detail


Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change.
MedLine Citation:
PMID:  20696979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To determine rates of visual field change associated with risk factors for progression in the Canadian Glaucoma Study (abnormal anticardiolipin antibody level, age, female sex, and mean follow-up intraocular pressure [IOP]), and to evaluate the effect of IOP reduction on subsequent rates of visual field change in progressing patients.
METHODS: Two hundred sixteen patients (median age, 65.2 years) were followed up at 4-month intervals with perimetry and were monitored for progression. Patients reaching an end point based on total deviation analysis underwent 20% or greater reduction in IOP. Rates of mean deviation (MD) change were calculated.
RESULTS: Patients with 0, 1, and 2 end points had a median of 18, 23, and 25 examinations, respectively. The median MD rate in progressing patients prior to the first end point was significantly worse compared with those with no progression (-0.35 and 0.05 dB/y, respectively). An abnormal anticardiolipin antibody level was associated with a significantly worse MD rate compared with a normal anticardiolipin antibody level (-0.57 and -0.03 dB/y, respectively). Increasing age was associated with a worse MD rate, but female sex and mean follow-up IOP were not. After the first end point, the median IOP decreased from 18.0 to 14.8 mm Hg (20% in individual patients), resulting in a significant MD rate change from -0.36 to -0.11 dB/y.
CONCLUSIONS: Patients with abnormal anticardiolipin antibody levels and increasing age had faster visual field change. Modest IOP reduction in progressing patients significantly ameliorated the rate of visual field decline.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00262626.
Authors:
Balwantray C Chauhan; Frederick S Mikelberg; Paul H Artes; A Gordon Balazsi; Raymond P LeBlanc; Mark R Lesk; Marcelo T Nicolela; Graham E Trope;
Related Documents :
7395959 - Ocular inflammation in reiter's disease after salmonella enteritis.
18504599 - Use of laser flare-cell photometry to quantify intraocular inflammation in patients wit...
7052559 - Blue field entoptoscopy and ver in preoperative cataract evaluation.
12567109 - Hyperhomocystinemia in pseudoexfoliation glaucoma.
7322499 - Rubeola keratitis.
11369379 - Clinical and specular microscopic manifestations of iridocorneal endothelial syndrome.
15764199 - Piperacillin-resistant escherichia coli bacteraemia: relation to empiric therapy and cl...
8596849 - Azygos blood flow in cirrhosis: measurement with mr imaging and correlation with varice...
2929289 - Arthroscopic resection of meniscal flaps of the knee.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2010-08-09
Journal Detail:
Title:  Archives of ophthalmology     Volume:  128     ISSN:  1538-3601     ISO Abbreviation:  Arch. Ophthalmol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-12     Completed Date:  2010-10-27     Revised Date:  2010-12-27    
Medline Journal Info:
Nlm Unique ID:  7706534     Medline TA:  Arch Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1249-55     Citation Subset:  AIM; IM    
Affiliation:
Department of Ophthalmology and Visual Sciences, Dalhousie University, Victoria, Halifax, Nova Scotia B3H 2Y9, Canada. bal@dal.ca
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00262626
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Anticardiolipin / blood
Disease Progression
Female
Follow-Up Studies
Glaucoma, Open-Angle / immunology,  physiopathology*
Humans
Intraocular Pressure / physiology*
Male
Middle Aged
Prospective Studies
Risk Factors
Tonometry, Ocular
Vision Disorders / physiopathology*
Visual Acuity / physiology
Visual Field Tests
Visual Fields / physiology*
Chemical
Reg. No./Substance:
0/Antibodies, Anticardiolipin
Investigator
Investigator/Affiliation:
Paul H Arrtes / ; Balwantray C Chauhan / ; Raymond P LeBlanc / ; Marcelo T Nicolela / ; Paul E Rafuse / ; David M Andrews / ; Mohammad Humayun / ; James MacNeill / ; Andrew C Orr / ; John H Quigley / ; George A Sapp / ; Christine A MacDonald / ; Helen M Sauveur / ; Sara L Lavender / ; A Gordon Balazsi / ; Oscar P Kasner / ; Nabil E Saheb / ; Alan J Coffey / ; W Edward Connolly / ; Marino J Discepola / ; Conrad C Kavalec / ; Susan K Lindley / ; Marc Mullie / ; Pearl Alexander / ; Bonnie May / ; Gordon R Douglas / ; Stephen M Drance / ; Frederick S Mikelberg / ; Jeffrey A Blicker / ; Robin S Cottle / ; Vincent Wong / ; Zarina Pardhan / ; Mark R Lesk / ; Pearl Alexander / ; Bonnie May / ; Yvonne M Buys / ; John G Flanagan / ; Graham E Trope / ; Catherine M Birt / ; Michael W Easterbrook / ; William G Macrae / ; Samuel N Markowitz / ; Maureen Wolpert / ; Emad Eskander / ; Christine A Macgillivray / ; Balwantray C Chauhan / ; Erin Hicks / ; Kathryn Patterson / ; Andrew Vassallo / ; Pantelis Andreou / ; Balwantray C Chauhan / ; Frederick S Mikelberg / ; A Gordon Balazsi / ; Raymond P LeBlanc / ; Mark R Lesk / ; Graham E Trope / ; Frederick S Mikelberg / ; Raymond P LeBlanc / ; Graham E Trope /
Comments/Corrections
Erratum In:
Arch Ophthalmol. 2010 Dec;128(12):1633

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans.
Next Document:  Monitoring Adherence to Medication by Measuring Change in Blood Pressure.